Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Johnson & Johnson (JNJ) stock in plain English

Free brief · no signupStart here
JNJPublished Nov 19, 2026
Johnson & Johnson
Healthcare · Drug Manufacturers - General
Manufactures pharmaceuticals for immunology, oncology, and neuroscience, along with surgical and orthopaedic devices.
Assets:
Blockbuster drug portfolioGenerates tens of billions annually from flagship therapies like Darzalex, Stelara, and Tremfya.
MedTech divisionProduces joint implants, robotic surgical systems, and cardiovascular tools across dozens of plants.
130,000 employeesStaff operates research laboratories, manufacturing sites, and commercial offices in over 60 countries.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

58
OPS ScoreOperating finances
Latest quote
-2.04%$267.14
$643.09B
40.5×
$99.40B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was JNJ. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Johnson & Johnson (JNJ) do?

Johnson & Johnson (JNJ) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures pharmaceuticals for immunology, oncology, and neuroscience, along with surgical and orthopaedic devices. It develops prescription drugs and surgical medical devices across a global network of specialized facilities. It is worth $643.09B on the market and sold $99.40B over the last year.

Market cap
$643.09B
P/E ratio
40.5×
Annual sales
$99.40B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 19, 2026

Brands and businesses behind JNJ

  • Stelara: Prescription biologic generating revenue by treating immune-mediated conditions such as plaque psoriasis and Crohn disease.
  • Darzalex: Cancer therapy medicine earning substantial revenue from treating patients with multiple myeloma.
  • Tremfya: Targeted biologic injection earning revenue by treating moderate to severe plaque psoriasis and active psoriatic arthritis.
  • DePuy Synthes: Orthopaedics business selling joint reconstruction implants, surgical power tools, and spinal repair hardware to hospitals.
  • Ethicon: Surgical brand earning revenue by selling surgical sutures, mechanical staplers, and advanced energy-cutting devices.
  • Biosense Webster: Electrophysiology unit generating revenue by selling specialized catheters and diagnostic mapping systems for heart arrhythmias.

JNJ’s flags, in plain English

Each flag is a number from Johnson & Johnson’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Wide Gross Margin

Gross margin of 67.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Low debt

Low debt, only 55% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 16.2%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Priced for Perfection

Priced at 40.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about JNJ

How big is Johnson & Johnson?

Johnson & Johnson’s market cap is $643.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $99.40B: what customers paid the company over the last year, before any costs.

What is JNJ’s P/E ratio?

JNJ’s P/E ratio is 40.5×. Investors pay about 40.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with JNJ?

Tens of thousands of active lawsuits claim talc in legacy consumer baby powder caused ovarian cancer and mesothelioma. That is one risk on Johnson & Johnson’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Johnson & Johnson’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. JNJ’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card